Mediwound Ltd Ord Sh (MDWD)

$18.29 +0.21 (1.16%)
Market Cap 161.80M
Revenue (ttm) 20.22M
Net Income (ttm) -30.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -149.46%
Debt to Equity Ratio 0.00
Volume 32,800
Avg Vol 77,450
Day's Range N/A - N/A
Shares Out 10.81M
Stochastic %K 84%
Beta 0.50
Analysts Strong Sell
Price Target $31.00

Latest News on MDWD

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Apr 28, 2025, 8:00 AM EDT - 23 hours ago

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 12:10 PM EDT - 5 weeks ago

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 7:00 AM EDT - 5 weeks ago

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 2 months ago

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Feb 25, 2025, 8:00 AM EST - 2 months ago

MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

Feb 24, 2025, 8:00 AM EST - 2 months ago

MediWound to Present at the 45th Annual TD Cowen Health Care Conference

MediWound to launch Phase III trial for venous leg ulcers

Feb 12, 2025, 8:12 AM EST - 2 months ago

MediWound to launch Phase III trial for venous leg ulcers

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

Feb 12, 2025, 7:00 AM EST - 2 months ago

MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 1:46 PM EST - 5 months ago

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 26, 2024, 7:00 AM EST - 5 months ago

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

MediWound Is A Healthy Investment

Oct 29, 2024, 10:49 AM EDT - 6 months ago

MediWound Is A Healthy Investment

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

Oct 10, 2024, 7:00 AM EDT - 7 months ago

MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

Aug 15, 2024, 4:15 PM EDT - 9 months ago

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 3:00 PM EDT - 9 months ago

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 14, 2024, 7:00 AM EDT - 9 months ago

MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

Aug 5, 2024, 7:30 AM EDT - 9 months ago

MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)

MediWound to Report Second Quarter 2024 Financial Results

Aug 2, 2024, 8:00 AM EDT - 9 months ago

MediWound to Report Second Quarter 2024 Financial Results

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

Jul 29, 2024, 8:00 AM EDT - 9 months ago

MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Jul 16, 2024, 7:30 AM EDT - 10 months ago

MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Jul 15, 2024, 7:32 AM EDT - 10 months ago

Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

MediWound Announces $25 Million Strategic Private Placement Financing

Jul 15, 2024, 7:00 AM EDT - 10 months ago

MediWound Announces $25 Million Strategic Private Placement Financing

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

May 29, 2024, 11:35 AM EDT - 11 months ago

MediWound Ltd. (MDWD) Q1 2024 Earnings Call Transcript

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 29, 2024, 7:00 AM EDT - 11 months ago

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

MediWound to Report First Quarter 2024 Financial Results

May 22, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report First Quarter 2024 Financial Results

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

Apr 25, 2024, 8:00 AM EDT - 1 year ago

MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 11:35 AM EDT - 1 year ago

MediWound Ltd. (MDWD) Q4 2023 Earnings Call Transcript

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024, 8:00 AM EDT - 1 year ago

MediWound to Report Fourth Quarter and Full Year 2023 Financial Results

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

Feb 12, 2024, 7:00 AM EST - 1 year ago

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

MediWound to Participate in Two Upcoming Investor Conferences

Feb 5, 2024, 8:00 AM EST - 1 year ago

MediWound to Participate in Two Upcoming Investor Conferences

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

Jan 9, 2024, 7:00 AM EST - 1 year ago

MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Dec 28, 2023, 7:00 AM EST - 1 year ago

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Dec 21, 2023, 8:00 AM EST - 1 year ago

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript

Nov 21, 2023, 1:14 PM EST - 1 year ago

MediWound Ltd. (MDWD) Q3 2023 Earnings Call Transcript

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 21, 2023, 7:02 AM EST - 1 year ago

MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

Nov 21, 2023, 7:00 AM EST - 1 year ago

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

MediWound to Report Third Quarter 2023 Financial Results

Nov 14, 2023, 8:02 AM EST - 1 year ago

MediWound to Report Third Quarter 2023 Financial Results

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

Nov 13, 2023, 7:00 AM EST - 1 year ago

MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

Nov 8, 2023, 7:00 AM EST - 1 year ago

MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

Oct 11, 2023, 6:00 AM EDT - 1 year ago

MediWound Announces Collaboration with 3M on EscharEx® Phase III Study

MediWound Deploys NexoBrid® for Emergency Supply

Oct 9, 2023, 7:34 AM EDT - 1 year ago

MediWound Deploys NexoBrid® for Emergency Supply

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

Sep 21, 2023, 6:00 AM EDT - 1 year ago

MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults

MediWound's NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

Sep 11, 2023, 8:00 AM EDT - 1 year ago

MediWound's NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress

MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 1 year ago

MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference

MediWound Ltd. (MDWD) Q2 2023 Earnings Call Transcript

Aug 16, 2023, 1:49 PM EDT - 1 year ago

MediWound Ltd. (MDWD) Q2 2023 Earnings Call Transcript

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

Aug 15, 2023, 4:03 PM EDT - 1 year ago

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

Aug 15, 2023, 4:02 PM EDT - 1 year ago

MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

Aug 15, 2023, 4:01 PM EDT - 1 year ago

MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study

MediWound to Report Second Quarter 2023 Financial Results

Aug 7, 2023, 8:00 AM EDT - 1 year ago

MediWound to Report Second Quarter 2023 Financial Results

MediWound Announces Commercial Launch of NexoBrid® in Japan

Aug 1, 2023, 7:30 AM EDT - 1 year ago

MediWound Announces Commercial Launch of NexoBrid® in Japan